Hall Laurie J Trustee Cuts Stock Holdings in AbbVie Inc. $ABBV

Hall Laurie J Trustee cut its holdings in AbbVie Inc. (NYSE:ABBV) by 15.0% in the third quarter, Holdings Channel reports. The fund owned 11,655 shares of the company’s stock after selling 2,050 shares during the quarter. Hall Laurie J Trustee’s holdings in AbbVie were worth $3,049,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Colton Groome Financial Advisors LLC grew its stake in AbbVie by 50.2% in the third quarter. Colton Groome Financial Advisors LLC now owns 8,274 shares of the company’s stock valued at $2,165,000 after purchasing an additional 2,767 shares during the last quarter. Legacy Private Trust Co. lifted its stake in shares of AbbVie by 0.6% during the third quarter. Legacy Private Trust Co. now owns 33,361 shares of the company’s stock worth $8,727,000 after buying an additional 210 shares during the period. Tompkins Financial Corp grew its stake in AbbVie by 0.4% during the 3rd quarter. Tompkins Financial Corp now owns 35,524 shares of the company’s stock valued at $9,293,000 after purchasing an additional 156 shares during the last quarter. Adelphi Trust Co increased its holdings in AbbVie by 1.9% in the 3rd quarter. Adelphi Trust Co now owns 10,668 shares of the company’s stock worth $2,791,000 after buying an additional 204 shares during the period. Finally, Heartwood Wealth Advisors LLC raised its stake in shares of AbbVie by 6.5% during the 3rd quarter. Heartwood Wealth Advisors LLC now owns 1,116 shares of the company’s stock valued at $292,000 after buying an additional 68 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Up 0.3%

NYSE ABBV traded up $0.89 during trading hours on Tuesday, reaching $266.65. The company had a trading volume of 4,500,600 shares, compared to its average volume of 6,436,153. The stock has a 50-day moving average of $258.05 and a 200 day moving average of $235.01. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $269.39. The stock has a market capitalization of $471.11 billion, a P/E ratio of 75.32, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Argus increased their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and raised their target price for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Barclays raised their price objective on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Wells Fargo & Company lifted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Finally, BNP Paribas Exane increased their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $273.82.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong Phase 3 lymphoma results: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma. The combination reduced the risk of disease progression or death by 51% versus R-CHOP alone, potentially positioning Epkinly as a frontline treatment standard and creating a larger commercial opportunity. The companies plan to discuss the results with global regulators. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts raise their outlook: Scotiabank lifted its ABBV price target from $280 to $320 and maintained a “sector outperform” rating. HSBC separately outlined a bullish case for a potential $315 target, citing AbbVie’s pipeline and growth prospects. Wall Street’s average recommendation remains equivalent to “Buy,” although analyst optimism is already reflected in the stock’s elevated valuation. Scotiabank raises AbbVie price target
• Positive Sentiment: Pipeline diversification: Coverage highlighted AbbVie’s newly approved Parkinson’s disease pill, described as the first FDA-approved selective D1/D5 therapy, adding another potential growth driver beyond immunology and oncology.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter report, expected later this month. Results and management’s outlook will be important tests for the stock after its substantial rally.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie incorporated $216 million of acquired in-process research and development and milestone expenses into its third-quarter outlook, reducing adjusted EPS guidance to $3.73–$3.77 from the prior range of $3.87–$3.91. Full-year adjusted EPS guidance was also reduced by $0.11 to $13.76–$13.96, creating a modest earnings headwind. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Pricing uncertainty: AbbVie’s participation in a federal 340B rebate pilot ahead of 2027, together with an anticipated Medicare price reduction for Vraylar, could pressure future pricing and margins, though the near-term financial impact remains uncertain.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.